Purpose: The aim of our study was to share our experience with antivascular endothelial growth factor (anti-VEgF) injections in the treatment of neovascular age-related macular degeneration (naMd) in a realworld setting.
A ge-related macular degeneration (aMd) is a multifactorial disease predominantly affecting the central macula and is a major ophthalmic concern across the globe. With increased life expectancy coupled with growing risk factors-particularly dietary habits, smoking, hypertension, and obesity-the incidence of aMd is expected to double by 2020.
1 the global Burden of disease study 2010 reported an exponential increase of 160% in vision-related years lived with disability due to aMd.
2 recent studies from an indian subgroup have described aMd to be the leading cause of legal blindness affecting 6.8% of the indian population aged between 40 and 79 years. age-related macular degeneration can broadly be divided into 2 forms, vascular and dry. advances in imaging technology along with an increased understanding of the disease have led to a paradigm shift in the management of neovascular aMd (naMd). Vascular endothelial growth factor (VEgF) is elucidated to be the main suspect behind the new vessels in naMd. development of molecules targeting VEgF such as ranibizumab, bevacizumab, and pegaptinib was a major breakthrough in the treatment of naMd. anti-VEgF was accepted as the standard of care treatment after the landmark Marina and ancHor clinical trials, 2 multicenter, randomized, controlled, clinical trials that studied the efficacy of monthly intravitreal anti-VEgF injections in naMd patients. However, monthly injections have added a heavy financial burden on patients with chronic naMd. subsequently, the Pronto and HarBor trials demonstrated the advantages of giving intravitreal anti-VEgF injections on a pro re nata (Prn) or "as needed" basis. the current protocol of treatment practiced across various Western and European countries is a "treat and extend" 3 or "treat and observe" 4 regimen. in the real-world observational aura study, investigators observed a good initial response to therapy, which subsequently declined over time.
5 despite the various protocols established, what happens in a real-world scenario where patients do not abide by these protocols or have an irregular follow-up has not been studied in a developing country like india. additionally, various factors like the cost of transportation, access to medical care, and treatment affordability are major limitations. thus, the use of guidelines laid out in various clinical trials in day-to-day practice is not practical. Hence, real-world observations can differ from the guidelines and results of various clinical trials. We aimed to study the results of treating naMd patients with antiVEgF in our clinic and evaluate if they were different from that of controlled trials. materials and methods study design the arMour (anti-VEgF in neovascular age-related Macular degeneration-our understanding in a real-World indian setting) study is a retrospective, observational, noninterventional, longitudinal study involving 119 eyes of 94 patients with naMd over 12 months. this study was designed, implemented, and reported in accordance with the ethical principles laid out in the declaration of Helsinki. inclusion criteria for this study consisted of patients with treatment-naive choroidal neovascular membrane (cnVM) secondary to naMd who were treated with anti-VEgF with a minimum follow-up of 12 months with regular follow-up at 1 month, 3 months, and 12 months. Patients who had comorbid ocular conditions or who had (−10.40-70.71) 6.6970 (1.28-12.12) 23.00 (−10.13-56.13) received previous treatment with anti-VEgF were not included in this study. additionally, patients who were switched to another molecule during the follow-up period were not included in the study. We followed the protocol of treating all patients as per a "treat and observe" regimen with 3 loading doses of anti-VEgF. However, on retrospective analysis, we found that a sizeable proportion did not adhere to the treatment schedule as described above. We therefore divided the patients into 2 groups: group 1 (compliant group) included patients who were compliant with the protocol and group 2 (noncompliant group) those who did not adhere to the protocol. on each visit, patients underwent a detailed ophthalmic examination and were imaged using spectral-domain optical coherence tomography (sd-oct). data was collected from visits at baseline, at month 1, after the loading visit (arbitrarily at around 3 months), and annually (final visit at around 12 months).
treatment endpoints and retreatment in both groups, response to treatment was monitored by evaluating the anatomical response on sd-oct. Patients with persistent retinal thickening or subretinal fluid on oct or fresh hemorrhage on fundus evaluation received reinjection; others were observed and advised to review monthly. the numbers of anti-VEgF injections were recorded across the 12-month observational period.
outcome measures the primary outcome measures of this study were mean change in corrected distance visual acuity (cdVa) and central subfield thickness (csFt) from baseline to months 3 and 12. corrected distance visual acuity was assessed by means of snellen visual acuity chart. the snellen visual acuity was converted into Early treatment diabetic retinopathy study (Etdrs) letters using a standardized formula.
6 central subfield thickness was measured using the central 1-mm circle of the Etdrs grid on the scanned oct image. secondary outcome measures were the average number of injections in each group, differences in response to the various anti-VEgF molecules and dosing schedules, and factors affecting the visual outcome at the end of 12 months. Based on sdoct, cnVMs were classified into 2 types: type 1 was defined as that located below the retinal pigment epithelium (rPE), and type 2 was subretinal as described by gass.
7 results from both the groups were subsequently compared. statistical analysis statistical analysis was done using iBM sPss (version 22.0 for Mac). corrected distance visual acuity in Etdrs letters, sex, age, number of injections, and csFt at baseline were compared between the 2 groups. at the postloading and annual visit, the gain in Etdrs letters and change in csFt were compared between the 2 groups. independent t test was used for quantitative variables and χ 2 test for categorical variables. For all analyses, a P value less than 0.05 was considered statistically significant. naive analyses were done using spearman correlation to assess which variables showed a significant correlation with the number of letters gained at 3 and 12 months. these variables were then used in the multivariate analysis. results a total of 119 eyes were included in this study, with an average age of 72.3 [95% confidence interval (ci), 70.8-73.8] years. the male-to-female ratio was 73:46. the mean presenting visual acuity (CDVA) was 45.77 ± 26.54 ETDRS letters (95% CI, 40.96-50.59) and the average initial csFt was 385.9 µm (95% ci, 361.4-410.4 µm). at 3 months' follow-up, the average number of letters gained was around 9 ETDRS letters (95% CI, 4.91-12.87) and the average decrease in csFt from baseline was 57.2 µm (95% ci, 28.7-85.7 µm). at 12 months, the average number of letters gained was 9.64 ETDRS letters (95% CI, 5.39-13.89) and the average decrease in csFt from baseline was 43.7 µm (95% ci, 15.9-71.4 µm).
differences in outcomes based on Compliance With Protocol the average number of injections given in group 1 was 4.98 (95% ci, 4.5-5.5) and in group 2 was 3.7 (95% ci, 3.4-4.1; P < 0.001; Fig. 1 ). Bevacizumab was given more frequently in group 2 (35:54) compared with more frequent ranibizumab in group 1 (18:12) and this difference was statistically significant (P = 0.04). the decrease in csFt at the postloading visit was greater in group 1 (90.89 µm; 95% ci, 51.9-129.8 µm) than in group 2 (30.15 µm; 95% ci, 10.4-70.7 µm; P = 0.033). We observed that 36.97% (44 of 119 eyes) of patients gained 15 or more letters at 12 months' follow-up. subgroup analysis showed that 43.39% (23 of 53 eyes) and 31.82% (21 of 66 eyes) in groups 1 and 2, respectively, gained 15 or more Etdrs letters at 12 months' follow-up (P = 0.193). overall, we observed that 77.31% (92 of 119 eyes) of patients either maintained (no change from baseline visual acuity at 12 months) or had improved visual acuity at 12 months' follow-up. a similar visual outcome was observed in both groups [group 1, 83.01% (44 of 53 eyes); group 2, 72.73% (48 of 66 eyes); P = 0.183] who either maintained or had improved visual acuity (table 1).
differences in outcomes based on VeGF molecule
there were no differences in the preinjection variables. the number of letters gained differed significantly between bevacizumab and ranibizumab. at 3 months, the average number of letters gained in the bevacizumab group was 5.58 (95% ci, 1.13 to 10.04) and in the ranibizumab group was 18.70 Etdrs letters (95% ci, 10.66 to 26.74; P = 0.006; Fig. 2 ) while at 12 months it was 7.55 Etdrs letters (95% ci, 2.85 to 12.25) in the bevacizumab group and 15.83 Etdrs letters in the ranibizumab group (95% ci, 6.14 to 25.52; P = 0.125; Fig. 3) . there was no significant difference between the anatomical outcome variables (table 2).
significant Correlations corrected distance visual acuity at 3 months was found to be significantly correlated with the type of drug molecule (r = 0.278; P = 0.002), csFt at 3 months (r = 0.310; P = 0.001), type of cnVM (r = 0.229; P = 0.012), and baseline visual acuity (r = −0.469; P = 0.000).
corrected distance visual acuity at 12 months was found to be significantly correlated with the type of drug molecule (r = 0.201; The visual acuity at 3 months in the bevacizumab and ranibizumab groups. P = 0.028), csFt at 3 months (r = 0.208; P = 0.023) and at 12 months (r = 0.331; P = 0.000), baseline visual acuity (r = −0.484; P = 0.000), and cdVa at 3 months (r = 0.705; P = 0.000).
these variables were further evaluated with multivariate analysis.
Factors influencing number of letters Gained
at 3 months' follow-up, baseline visual acuity (beta = −0.375; P = 0.000), change in csFt at 3 months (beta = 0.034; P = 0.002), and the choice of drug (beta = 11.24; P = 0.004) significantly influenced the number of letters gained, whereas the type of cnVM was not found to be significant on multivariate analysis (table 3) .
at 12 months' follow-up, baseline visual acuity (beta = −0.128; P = 0.043), the number of letters gained at 3 months (beta = 0.659; P = 0.000), change in CSFT at 3 months (beta = −0.031; P = 0.043), and change in csFt at 12 months (beta = 0.052; P = 0.001) significantly influenced the number of letters gained. the choice of drug did not independently influence the number of letters gained at 12 months in the multivariate analysis. disCussion the Marina and ancHor trials observed significant gain in visual acuity with monthly anti-VEgF injections for naMd. results from these trials set the standard for treatment outcome and led to monthly ranibizumab treatment being approved for patients with naMd in the united states in 2006. With the obvious burden of repeated injections and visits, a few trials like Pronto and HarBor were designed to study the efficacy of the Prn dosing schedule. as patients were treated after signs of clinical activity on oct in the Pronto trial, the "treat and extend" regimen was studied in European countries. subsequently, the real-world observational aura study was done to understand the protocol-based treatment in a true real-world scenario where patients do not abide by the protocol. in this regimen, anti-VEgF injections are given until the signs of exudation are resolved and then the follow-up interval is individualized. if no sign of activity is seen, then the duration of follow-up is increased, but at every follow-up anti-VEgF was given.
in a total of 119 eyes with an average number of 4 injections, we observed that 77% of patients either maintained (no change from baseline visual acuity at 12 months) or had improved visual acuity at 12 months' follow-up. a comparable trend as seen within the 2 arms of the study (P = 0.183) shows that the dosing schedule did not have any influence on the number of letters gained. Baseline visual acuity, number of letters gained at 3 months, reduction in csFt at 3 months, and the reduction in csFt at 12 months significantly influenced the number of letters gained at the yearly follow-up.
in our study, only treatment-naive patients were included with no other ocular comorbid conditions, whereas in other realworld observational studies, the inclusion criteria were not clearly defined. Many patients (66 eyes, 55.46%) in our study did not follow the prescribed protocol. Hence, we evaluated vision gain in both arms (compliant and noncompliant) to understand the outcomes.
Mean visual acuity was comparable at baseline with no statistically significant difference (group 1, 43; group 2, 48 Etdrs letters). We observed an overall 9.9 Etdrs letter gain (at 12 months), which is comparable with vision gain reported by various pivotal clinical trials like ancHor, 8 Marina, 9 Pronto, 10 and HarBor 11 (11.3, 7.2, 9.3, and 8.2 letters, respectively) . However, other real-world observations like the luMiErE, 12 tWin, 13 and aura studies reported a gain of +3.2, +4.3, and +2.4 Etdrs letters at 1 year, respectively, which is less than our observation. despite more mean letters gained in the compliant group, intergroup variability at 12 months showed no statistical significance (P = 0.138).
We observed that 37% of patients gained 15 or more letters at 12 months' follow-up. this gain was comparable in magnitude between both groups (P = 0.193). this success can be correlated with other randomized clinical trials like Marina (33.8%), ancHor (40.3%), Pronto (35%), and is better than luMiErE (19.6%) and tWin (21.5%).
the average number of injections required in group 1 was 5, whereas fewer injections (3.7 injections) were required in group 2 over 12 months (P < 0.001). despite the lesser number of injections in the noncompliant group, vision gain was similar in both groups. additionally, the number of injections required in group 2 (3.7) was significantly less than other clinical trials and real-world studies (ancHor, 12; Marina, 12; Pronto, 5.6; luMiErE, 5.1; aura, 5.0) . this bodes well, as a comparable visual improvement was achieved with fewer injections, thereby decreasing the overall economic burden, risk for endophthalmitis, and other injection-related complications. though our sample size is small, these encouraging results can pave the way for future randomized controlled trials.
none of the previous real-world studies have correlated changes in central subfoveal thickness with vision gain, which we observed to be an important parameter affecting the visual outcome at 12 months.
in our clinical observation, the cdVa at 12 months was influenced by baseline visual acuity, gain in Etdrs letters at 3 months, and reduction in csFt at 3 and 12 months. likewise, cdVa at 3 months was affected by baseline visual acuity, change in csFt at 3 months, and the choice of drug. the cdVa at 3 months was not affected by the type of dosing schedule. However, the choice of drug that influenced vision gain at 3 months did not affect cdVa at 12 months. We found that ranibizumab helped in achieving better visual gain than bevacizumab indirectly by affecting vision gain at 3 months. this is contrary to the result of the landmark comparison of age-related Macular degeneration treatments trials. However, the choice of ranibizumab with more frequent dosing did not affect the overall gain in visual acuity at 12 months' follow-up. Further, ranibizumab is affordable to a limited number of uninsured patients. in the real-world clinical setting, such patients are sincere with their follow-up, take treatment as advised, and are intelligent enough to detect subtle changes in their visual acuity. this could be a possible explanation for the difference noted.
limitations of our study include a small sample size; however, the retrospective nature helps us describe a true real-world scenario. our study is limited by the short duration of follow-up, which we hypothesize is due to higher relative cost of treatment and lack of awareness in the indian population. Hence, it would be interesting to understand the nature of the disease in longer follow-up. a noninterventional trial, the sEVEn uP 14 study, evaluated outcomes 7-8 years after initiation of ranibizumab therapy and included 65 patients originally treated in the ancHor, Marina, and HoriZon studies. a mean of 6.8 anti-VEgF injections had been received since exit from the HoriZon study (mean of 3.4 years) and 43% of study eyes had stable or improved vision versus ancHor and Marina baseline measurements; 34% had declined by at least 15 letters. However, mean gain in vision since exit from HoriZon was significantly better in patients who had received 11 anti-VEgF injections, suggesting vision gain/stabilization may be partly related to injection frequency.
our study shows that the visual acuity gained is comparable with previous studies and is not affected by the type of treatment schedule. the noncompliant group (group 2) with significantly fewer injections achieved similar anatomical and functional outcomes when compared with the compliant group (group 1). ranibizumab achieved better vision gain at 3 months and indirectly affects vision gain at 12 months. the most important parameters affecting vision gain at 12 months were vision gain at 3 months and csFt at 12 months. Factors affecting visual gain at 3 months were choice of drug, baseline visual acuity, and csFt at 3 months. Hence, our study demonstrates a trend that a lower number of injections may produce comparable results to previously published trials; however, larger trials with longer follow-up are required to ascertain the same. 
